The progress of peptide vaccine clinical trials in gynecologic oncology

References

• Nishio H, Iwata T, Aoki D. Current status of cancer immunotherapy for gynecologic malignancies. Jpn J Clin Oncol. 2021;51(2):167–12. doi:10.1093/jjco/hyaa214.
   PubMed Web of Science ®Google Scholar
• Smalley Rumfield C, Pellom ST, Morillon YM II, Schlom J, Jochems C. Immunomodulation to enhance the efficacy of an HPV therapeutic vaccine. J Immunother Cancer. 2020;8(1):e000612. doi:10.1136/jitc-2020-000612.
   PubMed Web of Science ®Google Scholar
• Saxena M, van der Burg SH, Melief CJM, Bhardwaj N. Therapeutic cancer vaccines. Nat Rev Cancer. 2021;21(6):360–78. doi:10.1038/s41568-021-00346-0.
   PubMed Web of Science ®Google Scholar
• Schneble E, Clifton GT, Hale DF, Peoples GE. Peptide-Based cancer vaccine strategies and clinical results. Methods Mol Biol. 2016;1403:797–817.
   PubMedGoogle Scholar
• Aranda F, Vacchelli E, Eggermont A, Galon J, Sautès-Fridman C, Tartour E, Zitvogel L, Kroemer G, Galluzzi L. Trial Watch: peptide vaccines in cancer therapy. Oncoimmunology. 2013;2(12):e26621. doi:10.4161/onci.26621.
   PubMed Web of Science ®Google Scholar
• Bezu L, Kepp O, Cerrato G, Pol J, Fucikova J, Spisek R, Zitvogel L, Kroemer G, Galluzzi L. Trial watch: peptide-based vaccines in anticancer therapy. Oncoimmunology. 2018;7(12):e1511506. doi:10.1080/2162402X.2018.1511506.
   PubMed Web of Science ®Google Scholar
• Gerner MY, Casey KA, Kastenmuller W, Germain RN. Dendritic cell and antigen dispersal landscapes regulate T cell immunity. J Exp Med. 2017;214(10):3105–22. doi:10.1084/jem.20170335.
   PubMed Web of Science ®Google Scholar
• Malonis RJ, Lai JR, Vergnolle O. Peptide-Based vaccines: current progress and future challenges. Chem Rev. 2020;120(6):3210–29. doi:10.1021/acs.chemrev.9b00472.
   PubMed Web of Science ®Google Scholar
• Parmiani G, Russo V, Maccalli C, Parolini D, Rizzo N, Maio M. Peptide-Based vaccines for cancer therapy. Hum Vaccines Immunother. 2014;10(11):3175–78. doi:10.4161/hv.29418.
   PubMed Web of Science ®Google Scholar
• Hirayama M, Nishimura Y. The present status and future prospects of peptide-based cancer vaccines. Int Immunol. 2016;28(7):319–28. doi:10.1093/intimm/dxw027.
   PubMed Web of Science ®Google Scholar
• Shi S, Zhu H, Xia X, Liang Z, Ma X, Sun B. Vaccine adjuvants: understanding the structure and mechanism of adjuvanticity. Vaccine. 2019;37(24):3167–78. doi:10.1016/j.vaccine.2019.04.055.
   PubMed Web of Science ®Google Scholar
• Firdaus FZ, Skwarczynski M, Toth I. Developments in vaccine adjuvants. Methods Mol Biol. 2022;2412:145–78.
   PubMedGoogle Scholar
• Sabbatini P, Tsuji T, Ferran L, Ritter E, Sedrak C, Tuballes K, Jungbluth AA, Ritter G, Aghajanian C, Bell-McGuinn K, et al. Phase I trial of overlapping long peptides from a tumor self-antigen and poly-ICLC shows rapid induction of integrated immune response in ovarian cancer patients. Clin Cancer Res. 2012;18(23):6497–508. doi:10.1158/1078-0432.CCR-12-2189.
   PubMed Web of Science ®Google Scholar
• Tsuji T, Sabbatini P, Jungbluth AA, Ritter E, Pan L, Ritter G, Ferran L, Spriggs D, Salazar AM, Gnjatic S, et al. Effect of Montanide and poly-ICLC adjuvant on human self/tumor antigen-specific CD4+ T cells in phase I overlapping long peptide vaccine trial. Cancer Immunol Res. 2013;1(5):340–50. doi:10.1158/2326-6066.CIR-13-0089.
   PubMed Web of Science ®Google Scholar
• Pol J, Bloy N, Buqué A, Eggermont A, Cremer I, Sautès-Fridman C, Galon J, Tartour E, Zitvogel L, Kroemer G, et al. Trial Watch: peptide-based anticancer vaccines. Oncoimmunology. 2015;4(4):e974411. doi:10.4161/2162402X.2014.974411.
   PubMed Web of Science ®Google Scholar
• Karkada M, Berinstein NL, Mansour M. Therapeutic vaccines and cancer: focus on DPX-0907. Biologics. 2014;8:27–38.
   PubMedGoogle Scholar
• Berinstein NL, Karkada M, Oza AM, Odunsi K, Villella JA, Nemunaitis JJ, Morse MA, Pejovic T, Bentley J, Buyse M, et al. Survivin-Targeted immunotherapy drives robust polyfunctional T cell generation and differentiation in advanced ovarian cancer patients. Oncoimmunology. 2015;4(8):e1026529. doi:10.1080/2162402X.2015.1026529.
   PubMed Web of Science ®Google Scholar
• Zamarin D, Walderich S, Holland A, Zhou Q, Iasonos AE, Torrisi JM, Merghoub T, Chesebrough LF, Mcdonnell AS, Gallagher JM, et al. Safety, immunogenicity, and clinical efficacy of durvalumab in combination with folate receptor alpha vaccine TPIV200 in patients with advanced ovarian cancer: a phase II trial. J Immunother Cancer. 2020;8(1):e000829. doi:10.1136/jitc-2020-000829.
   PubMed Web of Science ®Google Scholar
• Calvo Tardón M, Allard M, Dutoit V, Dietrich PY, Walker PR. Peptides as cancer vaccines. Curr Opin Pharmacol. 2019;47:20–26. doi:10.1016/j.coph.2019.01.007.
   PubMed Web of Science ®Google Scholar
• Melief CJM, Welters MJP, Vergote I, Kroep JR, Kenter GG, Ottevanger PB, Tjalma WAA, Denys H, van Poelgeest MIE, Nijman HW. Strong vaccine responses during chemotherapy are associated with prolonged cancer survival. Sci Transl Med. 2020;12(535):eaaz8235. doi:10.1126/scitranslmed.aaz8235.
   PubMed Web of Science ®Google Scholar
• Aldous AR, Dong JZ. Personalized neoantigen vaccines: a new approach to cancer immunotherapy. Bioorg Med Chem. 2018;26(10):2842–49. doi:10.1016/j.bmc.2017.10.021.
   PubMed Web of Science ®Google Scholar
• Maserat E, Nasiri Hooshmand M. Requirements of integrated computational approach for developing personalized cancer vaccines. Hum Vaccines Immunother. 2021;17(12):1–2.
   PubMed Web of Science ®Google Scholar
• Hu Z, Ott PA, Wu CJ. Towards personalized, tumour-specific, therapeutic vaccines for cancer. Nat Rev Immunol. 2018;18(3):168–82. doi:10.1038/nri.2017.131.
   PubMed Web of Science ®Google Scholar
• Pan RY, Chung WH, Chu MT, Chen SJ, Chen HC, Zheng L, Hung S-I. Recent development and clinical application of cancer vaccine: targeting neoantigens. J Immunol Res. 2018;2018:4325874. doi:10.1155/2018/4325874.
   PubMed Web of Science ®Google Scholar
• Domingos-Pereira S, Galliverti G, Hanahan D, Nardelli-Haefliger D. Carboplatin/paclitaxel, E7-vaccination and intravaginal CpG as tri-therapy towards efficient regression of genital HPV16 tumors. J Immunother Cancer. 2019;7:122.
   PubMed Web of Science ®Google Scholar
• Hoppe-Seyler K, Bossler F, Braun JA, Herrmann AL, Hoppe-Seyler F. The HPV E6/E7 oncogenes: key factors for viral carcinogenesis and therapeutic targets. Trends Microbiol. 2018;26(2):158–68. doi:10.1016/j.tim.2017.07.007.
   PubMed Web of Science ®Google Scholar
• Levine AJ. Targeting the P53 protein for cancer therapies: the translational impact of P53 research. Cancer Res. 2022;82(3):362–64. doi:10.1158/0008-5472.CAN-21-2709.
   PubMed Web of Science ®Google Scholar
• Dijkgraaf EM, Santegoets SJ, Reyners AK, Goedemans R, Nijman HW, van Poelgeest MI, van Erkel AR, Smit VTHBM, Daemen TAHH, van der Hoeven JJM, et al. A phase 1/2 study combining gemcitabine, Pegintron and p53 SLP vaccine in patients with platinum-resistant ovarian cancer. Oncotarget. 2015;6(31):32228–43. doi:10.18632/oncotarget.4772.
   PubMedGoogle Scholar
• Thomas R, Al-Khadairi G, Roelands J, Hendrickx W, Dermime S, Bedognetti D, Decock J. NY-ESO-1 based immunotherapy of cancer: current perspectives. Front Immunol. 2018;9:947. doi:10.3389/fimmu.2018.00947.
   PubMed Web of Science ®Google Scholar
• Ghaffari-Nazari H, Tavakkol-Afshari J, Jaafari MR, Tahaghoghi-Hajghorbani S, Masoumi E, Jalali SA, Khodarahmi R, Khodarahmi R. Improving multi-epitope long peptide vaccine potency by using a strategy that enhances CD4+ T help in BALB/c Mice. PloS One. 2015;10(11):e0142563. doi:10.1371/journal.pone.0142563.
   PubMed Web of Science ®Google Scholar
• Chen X, Yang J, Wang L, Liu B. Personalized neoantigen vaccination with synthetic long peptides: recent advances and future perspectives. Theranostics. 2020;10(13):6011–23. doi:10.7150/thno.38742.
   PubMed Web of Science ®Google Scholar
• Ma M, Liu J, Jin S, Wang L. Development of tumour peptide vaccines: from universalization to personalization. Scand J Immunol. 2020;91(6):e12875. doi:10.1111/sji.12875.
   PubMed Web of Science ®Google Scholar
• Sunita SA, Singh Y, Shukla P, Shukla P. Computational tools for modern vaccine development. Hum Vaccin Immunother. 2020;16(3):723–35. doi:10.1080/21645515.2019.1670035.
   PubMed Web of Science ®Google Scholar
• Hu Z, Leet DE, Allesøe RL, Oliveira G, Li S, Luoma AM, Liu J, Forman J, Huang T, Iorgulescu JB. Personal neoantigen vaccines induce persistent memory T cell responses and epitope spreading in patients with melanoma. Nat Med. 2021;27(3):515–25. doi:10.1038/s41591-020-01206-4.
   PubMed Web of Science ®Google Scholar
• Lee YS, Radford KJ. The role of dendritic cells in cancer. Int Rev Cell Mol Biol. 2019;348:123–78.
   PubMed Web of Science ®Google Scholar
• Cancel JC, Crozat K, Dalod M, Mattiuz R. Are conventional Type 1 dendritic cells critical for protective antitumor immunity and how? Front Immunol. 2019;10:9. doi:10.3389/fimmu.2019.00009.
   PubMed Web of Science ®Google Scholar
• Bol KF, Schreibelt G, Rabold K, Wculek SK, Schwarze JK, Dzionek A, Teijeira A, Kandalaft LE, Romero P, Coukos G, et al. The clinical application of cancer immunotherapy based on naturally circulating dendritic cells. J Immunother Cancer. 2019;7(1):109. doi:10.1186/s40425-019-0580-6.
   PubMedGoogle Scholar
• Wen R, Umeano AC, Kou Y, Xu J, Farooqi AA. Nanoparticle systems for cancer vaccine. Nanomedicine (London, England). 2019;14(5):627–48. doi:10.2217/nnm-2018-0147.
   PubMed Web of Science ®Google Scholar
• Gatti-Mays ME, Redman JM, Collins JM, Bilusic M. Cancer vaccines: enhanced immunogenic modulation through therapeutic combinations. Hum Vaccines Immunother. 2017;13(11):2561–74. doi:10.1080/21645515.2017.1364322.
   PubMed Web of Science ®Google Scholar
• Hinshaw DC, Shevde LA. The tumor microenvironment innately modulates cancer progression. Cancer Res. 2019;79(18):4557–66. doi:10.1158/0008-5472.CAN-18-3962.
   PubMed Web of Science ®Google Scholar
• Sousa LG, Rajapakshe K, Rodriguez Canales J, Chin RL, Feng L, Wang Q. ISA101 and nivolumab for HPV-16(+) cancer: updated clinical efficacy and immune correlates of response. J Immunother Cancer. 2022;10.
   Web of Science ®Google Scholar